McKesson Corporation McKesson Week Day 4: Prescription Technology Solutions

Research evidence excerpt

McKesson Corporation McKesson Week Day 4: Prescription Technology Solutions

J P M O R G A N North America Equity Research

15 May 2026

McKesson Corporation Overweight

MCK, MCK US

McKesson Week Day 4: Prescription Technology Price (14 May 26):$747.23

Solutions

Managed Care and Facilities

For Day 4 of McKesson Week, we have a deep dive into the company’s Prescription Lisa C. Gill AC

Technology Solutions (RxTS) segment. RxTS provides a variety of services to (1-212) 622-6466

stakeholders throughout the healthcare value chain, including manufacturers, lisa.c.gill@jpmorgan.com

payors, pharmacists, and patients. While it is not uncommon to hear John Stansel, CFA

pharmaceutical distributors speak to their technology and automation solutions as (1-212) 622-0083

well as value-added services, we believe this segment is differentiated given the john.stansel@jpmorgan.com

scale and growth of the platform. Following several impressive years in which Benjamin Rossi

performance was boosted by prior authorization offerings (particularly around (1-212) 622-9603

benjamin.rossi@jpmorgan.com

GLP-1s), RxTS remains a faster growing component of McKesson’s business, and

Cole Harris

we believe this segment will continue to deliver above-trend growth, with FY27 (1-212) 622-9068

guidance for AOI growth of +11% to +15%, with the midpoint at the high end of cole.harris@jpmorgan.com

the segment's long-term target of +10% to +13% AOI Growth. We are holding a J.P. Morgan Securities LLC

conference call this morning with MCK CEO Brian Tyler and CFO Britt Vitalone

at 9am Eastern. Please reach out to us or your J.P. Morgan sales rep to register.

• RxTS provides solutions targeting improved access, adherence, and

affordability in the healthcare delivery system. The company’s technology